Related Research Articles
Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.
Matuzumab is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania
Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck.
Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma and renal cell carcinoma.
Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.
Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene.
Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer, Phase II trials for colorectal cancer, non-small cell lung cancer, and ovarian cancer have been completed.
Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).
Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). It acts as an ALK and ROS1 inhibitor.
Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals. Several Phase II clinical trials were completed that investigated use of obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.
Motesanib is an experimental drug candidate originally developed by Amgen but later investigated by the Takeda Pharmaceutical Company. It is an orally administered small molecule belonging to angiokinase inhibitor class which acts as an antagonist of VEGF receptors, platelet-derived growth factor receptors, and stem cell factor receptors. It is used as the phosphate salt motesanib diphosphate. After clinical trials in thyroid cancer, non-small cell lung cancer, gastrointestinal stromal cancer, colorectal cancer, and breast cancer, the drug was not found to show sufficient efficacy for further development, and development was abandoned by Takeda.
Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.
TIGIT is an immune receptor present on some T cells and natural killer cells (NK). It is also identified as WUCAM and Vstm3. TIGIT could bind to CD155 (PVR) on dendritic cells (DCs), macrophages, etc. with high affinity, and also to CD112 (PVRL2) with lower affinity.
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
Apricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID). It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly-defined models of pancreatic cancer. It was also studied in clinical trials for non-small-cell lung cancer. Development was abandoned in 2015 due to poor clinical trial results.
Navitoclax is an experimental orally active anti-cancer drug, which is a Bcl-2 inhibitor similar in action to obatoclax.
RET inhibitors are targeted therapies that act on tumors with activating alterations in the RET proto-oncogene, such as point mutations or fusions. They fall under the category of the tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of cancer cells. Existing molecules fall in two main categories: the older multikinase inhibitors and the more recent selective inhibitors. Although RET alterations are found at low frequency in a broad range of tumors, the three main indications for RET inhibitors today are non-small cell lung cancer, medullary thyroid cancer and papillary thyroid cancer. As of 2020, up to 48 fusion partners have been catalogued in NSCLC rearrangements, with KIF5B and CCDC6 being the most prevalent. At least 10 different fusion variants have been described for KIF5B-RET, each with different breakpoints within the partner gene, but unclear clinical impact as of 2018.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.
Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is administered by infusion into a vein.
References
- ↑ Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan W.; Morgensztern, Daniel; Heist, Rebecca; Vokes, Everett; Spira, Alex; Angevin, Eric; Su, Wu-Chou; Hong, David S.; Strickler, John H.; Motwani, Monica; Dunbar, Martin; Parikh, Apurvasena; Noon, Elysa; Blot, Vincent; Wu, Jun; Kelly, Karen (10 February 2023). "Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer". Journal of Clinical Oncology. 41 (5): 1105–1115. doi:10.1200/JCO.22.00739. ISSN 0732-183X. PMC 9928626 .
- ↑ Fujiwara, Yutaka; Kenmotsu, Hirotsugu; Yamamoto, Noboru; Shimizu, Toshio; Yonemori, Kan; Ocampo, Christopher; Parikh, Apurvasena; Okubo, Sumiko; Fukasawa, Kazuteru; Murakami, Haruyasu (April 2021). "Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors". Cancer Medicine. 10 (7): 2350–2358. doi:10.1002/cam4.3815. ISSN 2045-7634. PMC 7982615 .
- ↑ Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan W.; Morgensztern, Daniel; Heist, Rebecca; Vokes, Everett; Angevin, Eric; Hong, David S.; Rybkin, Igor I.; Barve, Minal; Bauer, Todd M.; Delmonte, Angelo; Dunbar, Martin; Motwani, Monica; Parikh, Apurvasena; Noon, Elysa; Wu, Jun; Blot, Vincent; Kelly, Karen (January 2022). "A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC". JTO Clinical and Research Reports. 3 (1): 100262. doi:10.1016/j.jtocrr.2021.100262. PMC 8717236 .
- ↑ Waqar, Saiama N.; Redman, Mary W.; Arnold, Susanne M.; Hirsch, Fred R.; Mack, Philip C.; Schwartz, Lawrence H.; Gandara, David R.; Stinchcombe, Thomas E.; Leighl, Natasha B.; Ramalingam, Suresh S.; Tanna, Saloni H.; Raddin, Ryan S.; Minichiello, Katherine; Bradley, Jeffrey D.; Kelly, Karen; Herbst, Roy S.; Papadimitrakopoulou, Vassiliki A. (1 May 2021). "A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)". Clinical Lung Cancer. 22 (3): 170–177. doi:10.1016/j.cllc.2020.09.013. ISSN 1525-7304. PMC 8044254 .
- ↑ Strickler, John H.; Weekes, Colin D.; Nemunaitis, John; Ramanathan, Ramesh K.; Heist, Rebecca S.; Morgensztern, Daniel; Angevin, Eric; Bauer, Todd M.; Yue, Huibin; Motwani, Monica; Parikh, Apurvasena; Reilly, Edward B.; Afar, Daniel; Naumovski, Louie; Kelly, Karen (20 November 2018). "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors". Journal of Clinical Oncology. 36 (33): 3298–3306. doi: 10.1200/jco.2018.78.7697 .